205 related articles for article (PubMed ID: 30253728)
1. Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience.
Dada R; Zabani Y
J Oncol Pharm Pract; 2019 Oct; 25(7):1586-1589. PubMed ID: 30253728
[TBL] [Abstract][Full Text] [Related]
2. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
4. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
6. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Maruyama D; Terui Y; Yamamoto K; Fukuhara N; Choi I; Kuroda J; Ando K; Hattori A; Tobinai K
Jpn J Clin Oncol; 2020 Oct; 50(11):1265-1273. PubMed ID: 32776097
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
Ramchandren R; Domingo-Domènech E; Rueda A; Trněný M; Feldman TA; Lee HJ; Provencio M; Sillaber C; Cohen JB; Savage KJ; Willenbacher W; Ligon AH; Ouyang J; Redd R; Rodig SJ; Shipp MA; Sacchi M; Sumbul A; Armand P; Ansell SM
J Clin Oncol; 2019 Aug; 37(23):1997-2007. PubMed ID: 31112476
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC; Ansell SM
Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
17. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
18. An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
Wight JC; Hawkes EA; Berlangieri SU; Khor R; Grigg AP
Leuk Lymphoma; 2018 Nov; 59(11):2749-2751. PubMed ID: 29569979
[No Abstract] [Full Text] [Related]
19. Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma.
Kowata S; Seki Y; Tsukushi Y; Sato T; Asano K; Maeta T; Yashima-Abo A; Sasaki R; Okano Y; Oyake T; Ito S
Int J Hematol; 2023 Dec; 118(6):751-757. PubMed ID: 37488284
[TBL] [Abstract][Full Text] [Related]
20. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
